BICO enables and automates the life science lab of the future
press releases
02/19/25RegulatoryPublication of BICO Group AB: Year-end report 2024
02/18/25RegulatoryBICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 276m
11/26/24RegulatoryPublication of BICO Group Interim Report January-September 2024
11/22/24BICO Group AB (publ) has repurchased convertible bonds to a total nominal amount of SEK 118m
11/21/24RegulatoryBICO has entered into an agreement to divest Nanoscribe
10/18/24RegulatoryBICO’s Calendar for financial reporting: H2 2024 and 2025
10/09/24RegulatoryBICO Group AB’s Nomination Committee for the 2025 Annual General Meeting
08/20/24RegulatoryPublication of BICO Group Interim report January-June 2024
07/10/24RegulatoryAndréas Joersjö appointed as General Counsel for BICO Group AB
05/20/24RegulatoryBulletin from Annual General Meeting in BICO Group AB (publ)
05/13/24RegulatoryBICO publishes adjusted Annual and Sustainability Report 2023
05/07/24RegulatoryPublication of BICO Group Interim report January-March 2024
05/06/24RegulatoryBICO changes method for impairment test of goodwill resulting in retroactive impairment of goodwill for 2022 and 2023 and provides preliminary figures for Q1 2024
04/16/24RegulatoryNotice to attend the Annual General Meeting in BICO Group AB (publ)
03/15/24RegulatoryFounders leave after eight years
03/15/24RegulatoryBICO Publishes Annual and Sustainability Report 2023
02/20/24RegulatoryPublication of BICO Group Year-end report 2023
02/14/24RegulatoryBICO announces goodwill impairment of SEK 582m and provides preliminary figures for Q4 2023
12/04/23RegulatoryBICO company Biosero has signed an agreement to develop laboratory automation solutions to a value of 28 MUSD
11/14/23RegulatoryPublication of BICO Group interim report July – September 2023
11/13/23BICO has divested Ginolis
11/09/23RegulatoryBICO Group AB Nomination Committee 2024 AGM appointed
11/01/23RegulatoryBICO releases preliminary revenue, EBITDA, and cash flow from operating activities for Q3, 2023
08/22/23RegulatoryPublication of BICO Group interim report April – June 2023
08/21/23RegulatoryBICO announces goodwill impairment predominantly due to increased WACC, and write-downs of assets
08/21/23RegulatoryMaria Forss is appointed new President and CEO of BICO Group AB (publ)
05/09/23RegulatoryBulletin from Annual General Meeting in BICO Group AB (publ)
05/04/23RegulatoryPublication of BICO Group interim report January – March 2023
Calendar
Strategy BICO 2.0
BICO’s updated strategy was launched during the Capital Markets Day held on September 17, 2024, with focus on the Group’s strategic direction for sustainable profitable growth.
Lab Automation
One key commercial focus area in the updated strategy is enabling end-to-end lab automation. In addition, BICO has introduced a new business area structure where Lab Automation has been established as a stand alone business area.
Lab Automation is here to stay so why not explore what it is all about?
Bico by numbers
Net Sales OCTOBER-DECEMBER 2024
496
M SEK
Organic Growth OCTOBER-DECEMBER 2024
-12.1
%
Employees
650
+
Instruments in the Field
46000
+
Publications
11000
+
Countries
25
+
BICO News Feed
January 23, 2025
Bico BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
Bico BD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development
November 25, 2024
Cytena The Ultimate Guide to Viral Vector Production: Applications, Quality Control, and Efficient Manufacturing Strategies
Cytena The Ultimate Guide to Viral Vector Production: Applications, Quality Control, and Efficient Manufacturing Strategies
November 18, 2024
Cytena Strategies for Efficient Viral Vector Production for Gene Therapies
Cytena Strategies for Efficient Viral Vector Production for Gene Therapies
